biote Corp. | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 44.23 M

Revenue: As of FY2026 Q2, the actual value is USD 44.23 M, missing the estimate of USD 46.08 M.

EPS: As of FY2026 Q2, the actual value is USD -0.23.

EBIT: As of FY2026 Q2, the actual value is USD -4.949 M.

Second Quarter 2026 Financial Highlights

Revenue

biote Corp. reported total revenue of $44.2 million in the second quarter of 2026, marking a 9.5% decrease from $48.9 million in the prior-year period. Procedure revenue declined by 13.9% to $30.3 million, primarily due to a voluntary product recall. Conversely, dietary supplements revenue grew by 5.7% to $11.4 million.

Profitability

Gross profit margin for the second quarter of 2026 was 65.4%, a decrease from 71.6% in the second quarter of 2025, attributed to higher costs for replacement products and reduced manufacturing efficiencies. Operating income shifted to a loss of - $3.5 million in Q2 2026, down from an income of $10.8 million in Q2 2025, due to lower revenue, reduced gross profit, and higher operating expenses. Net loss for the quarter was - $7.4 million, compared to a net income of $3.9 million in Q2 2025. This net loss included a loss of - $0.8 million in Q2 2026 from changes in the fair value of earnout liabilities, compared to a loss of - $1.8 million in Q2 2025. Adjusted EBITDA decreased to $5.6 million from $15.2 million in the prior-year period, resulting in an Adjusted EBITDA margin of 12.6%, down from 31.1%.

Six Months Ended June 30, 2026 Financial Overview

Revenue

For the six months ended June 30, 2026, total revenue was $89.2 million, compared to $97.9 million for the same period in 2025.

Costs and Expenses

Cost of revenue for the six-month period was $29.3 million, up from $26.5 million in the prior year. Selling, general and administrative expenses increased to $60.2 million from $50.9 million.

Profitability

Income from operations for the six months ended June 30, 2026, was a loss of - $0.3 million, a significant decline from an income of $20.5 million in the prior year. Net loss for the six-month period was - $4.8 million, compared to a net income of $19.8 million in 2025. Adjusted EBITDA for the six months ended June 30, 2026, was $14.3 million, down from $28.9 million in the same period of 2025, with an Adjusted EBITDA margin of 16.0% compared to 29.6%.

Cash Flow

For the six months ended June 30, 2026, net cash provided by operating activities was $2.7 million, a decrease from $13.6 million in the same period of 2025. Net cash used in investing activities was - $3.8 million, remaining relatively stable compared to - $3.8 million in 2025. Net cash used in financing activities was - $11.9 million, an improvement from - $29.5 million in 2025. Cash and cash equivalents at the end of the period were $11.2 million, down from $19.6 million at June 30, 2025.

2026 Financial Outlook

biote Corp. has updated its full-year 2026 financial outlook, expecting revenue to be above $175 million and Adjusted EBITDA to be above $25 million. The company anticipates sequential improvement in procedure revenue in both the third and fourth quarters, despite expecting year-over-year procedure revenue to remain negative due to first-half disruptions. Dietary supplements revenue is projected to grow at a mid to high single-digit rate from 2025, consistent with prior guidance.